The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1591
ISSUE1591
February 10, 2020
Istradefylline (Nourianz) for Parkinson's Disease
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Istradefylline (Nourianz) for Parkinson's Disease
February 10, 2020 (Issue: 1591)
The FDA has approved istradefylline (Nourianz —
Kyowa Kirin), an oral adenosine A2A receptor antagonist,
for use as an adjunct to carbidopa/levodopa in adults
with Parkinson's disease (PD) who experience "off"
episodes. Istradefylline is the...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.